Lonza Group stock

LONN · SIX · CHF

Compare Lonza Group
CHF 663.00Change from previous close: −1.07%Absolute change: −CHF 7.20

Close · November 17, 2026

Price history

+23.84% over the period

1 year: from CHF 539.40 (November 17, 2025) to CHF 668.00 (November 17, 2026), +23.84%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 17, 2026CHF 668.00
October 30, 2026CHF 644.20
September 30, 2026CHF 575.20
August 31, 2026CHF 576.60
July 31, 2026CHF 562.20
June 30, 2026CHF 545.80
May 29, 2026CHF 500.40
April 30, 2026CHF 479.20
March 31, 2026CHF 504.80
February 27, 2026CHF 536.20
January 30, 2026CHF 525.00
December 30, 2025CHF 537.80
November 28, 2025CHF 550.00
November 17, 2025CHF 539.40

At a glance

  • The company

    Contract development and manufacturing organization providing CDMO services for biologics, advanced synthesis and specialized modalities to pharma and biotech companies worldwide

  • Latest results

    Quarter to June 30, 2026 · EPS CHF 8.12 (estimate CHF 8.24)

TickerLandia's take on Lonza Group

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk lowCHF 454.60
52-wk highCHF 675.60

−1.87% from the 52-week high

Analysts · 24 analysts

Average targetCHF 719.65+8.54% vs. price

Buy 21 · Hold 3 · Sell 0 · Buy

TickerLandia Fingerprint: Lonza Group

Compared with similar companies: very strong momentum.

Financials and price compared with 27 companies in the diagnostics & research industry, worldwide. Momentum and risk compared with 1,160 European stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 17, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Lonza Group is pricier than in the past and pricier than similar companies

On the latest fiscal year's earnings (2025), Lonza Group's P/E today is 51.5, above the median of its last 10 fiscal years (40.3; between 27.1 and 84.2 from 2016 to 2025). Lonza Group's P/E (trailing 12 months): 43.9, +43% against the median of a group of 10 similar companies (30.8).

P/E compared with its history

Compared with 10 similar companies

Lonza Group's metrics compared with similar companies
MetricLonza GroupPosition in the groupBand
P/E (trailing 12 months)43.9High
Forward P/E29.5High
Operating margin23.5%Middle
ROE12.9%Middle
Debt/equity0.51Middle

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Lonza Group. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

CHF 3.37B

Latest quarter · Q2 2026

Net income

CHF 591M

Latest quarter · Q2 2026

Quarterly net margin

17.5%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
CHF 46.31B
P/E
43.9
EPS
CHF 15.09
Volume
117.67K
Daily trading
€99.24M
Dividend yield
0.75%
Last ex-dividend on May 12, 2026

How Lonza Group is changing

All results
  • Revenue grew 7.7% a year on average over the last 5 years

  • Less cash than profit: free cash flow equal to -52% of net income

  • Shares outstanding down 6.3% in 5 years

Returns

Lonza Group returns with dividends

CHF 1,000 invested in Lonza Group 5 years ago, on November 17, 2021, would be worth CHF 936 today with dividends reinvested: −6.35% in total, −1.30% per year. On price alone it would be CHF 902 (−9.75%).

PeriodLonza GroupSMICHF 1,000 becomes
1 month+8.94%+4.53%CHF 1,089
6 months+41.24%+13.61%CHF 1,412
Year to date+24.21%+13.20%CHF 1,242
1 year+25.14%+19.22%CHF 1,251
3 years+92.95%+39.88%CHF 1,929
5 years−6.35%+19.20%CHF 936
10 years+334.84%+88.57%CHF 4,348

Over the last 6 months it has done better than 63% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. SMI: price only. Calculate your investment

The chart in detail

Lonza Group: technical analysis

Lonza Group is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 15.5% below its all-time closing high (CHF 784.60, September 6, 2021).

Trend
Upward
RSI (14 sessions)
67
Between 30 and 70
vs 200-session average
+21.73%

Support and resistance

Price areas where Lonza Group has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. No resistance above: the price is near the highs of the year
  2. Last priceCHF 663.00
  3. SupportCHF 593.53−10.48%3 touches, last on October 6, 2026
  4. SupportCHF 582.13−12.20%3 touches, last on August 11, 2026
  5. SupportCHF 554.60−16.35%3 touches, last on October 2, 2026

Volatility and risk

Over the last year it has moved roughly in line with the SMI.

Beta (1 year) vs SMI
0.91
Volatility (60 sessions, annualised)
21.1%
Largest fall in the last year
−17.52%

Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Lonza Group: seasonality

Average monthly price change over 27 years

+2.5%Jan+1.3%Feb+1.5%Mar+0.7%Apr+0.3%May−0.4%Jun+4.6%Jul−0.7%Aug−0.5%Sep+0.2%Oct+0.7%Nov+0.7%Dec

Over the last 27 years, the strongest month for Lonza Group has been July: +4.63% on average, positive in 20 years out of 27. The weakest has been August: −0.69% on average, positive in 14 years out of 27. November, the current month, has been positive in 13 years out of 26 (+0.70% on average).

Show chart data
MonthAverageMedianPositive years
January+2.52%+0.21%16 of 27
February+1.32%+0.67%17 of 27
March+1.47%+1.09%15 of 27
April+0.71%+1.63%15 of 27
May+0.31%+1.71%15 of 27
June−0.45%−0.58%11 of 27
July+4.63%+3.61%20 of 27
August−0.69%+0.11%14 of 27
September−0.50%−0.36%12 of 27
October+0.17%+4.33%18 of 27
November+0.70%−0.24%13 of 26
December+0.68%+1.73%16 of 27

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Lonza Group and its competitors

Contract development and manufacturing for pharma and biotech companies forms the core of Lonza Group AG, which serves clients in Europe, North and Central America, Latin America, Asia, Australia and New Zealand. Its Integrated Biologics unit covers biologics services from clinical development through drug substance and drug product manufacturing, while Advanced Synthesis makes antibody-drug conjugates, related bioconjugates and potent active ingredients. The Specialized Modalities unit spans cell and gene, microbial, bioscience and mRNA technologies.

Headquarters
Basel, Switzerland
Employees
20,141
Founded
1897
Chief executive
Wolfgang Wienand
Lonza Group and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Lonza GroupLONN$55.11B23.5%43.9+41.24%
Eurofins ScientificERF$16.53B14.1%30.5+44.16%
bioMérieuxBIM$11.7B16.0%23.2+26.52%
QiagenQIA$10.3B26.7%27.3+58.79%
DiaSorinDIA$4.56B22.3%31.0+16.24%
DiagnostykaDIA$1.29B14.9%20.3−5.09%

Same industry or related industries, similar size. Compare Lonza Group with its competitors · Full profile